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Abstract
Background: To evaluate imprint cytology in the context of specimens with microcalcifications derived
from Vacuum-Assisted Breast Biopsy (VABB).
Patients and methods: A total of 93 women with microcalcifications BI-RADS 3 and 4 underwent VABB
and imprint samples were examined. VABB was performed on Fischer's table using 11-gauge Mammotome
vacuum probes. A mammogram of the cores after the procedure confirmed the excision of
microcalcifications. For the application of imprint cytology, the cores with microcalcifications confirmed
by mammogram were gently rolled against glass microscope slides and thus imprint smears were made.
For rapid preliminary diagnosis Diff-Quick stain, modified Papanicolaou stain and May Grunwald Giemsa
were used. Afterwards, the core was dipped into a CytoRich Red Collection fluid for a few seconds in
order to obtain samples with the use of the specimen wash. After the completion of cytological
procedures, the core was prepared for routine histological study. The pathologist was blind to the
preliminary cytological results. The cytological and pathological diagnoses were comparatively evaluated.
Results: According to the pathological examination, 73 lesions were benign, 15 lesions were carcinomas
(12 ductal carcinomas in situ, 3 invasive ductal carcinomas), and 5 lesions were precursor: 3 cases of
atypical ductal hyperplasia (ADH) and 2 cases of lobular neoplasia (LN). The observed sensitivity and
specificity of the cytological imprints for cancer were 100% (one-sided, 97.5% CI: 78.2%–100%). Only one
case of ADH could be detected by imprint cytology. Neither of the two LN cases was detected by the
imprints. The imprints were uninformative in 11 out of 93 cases (11.8%). There was no uninformative case
among women with malignancy.
Conclusion: Imprint cytology provides a rapid, accurate preliminary diagnosis in a few minutes. This
method might contribute to the diagnosis of early breast cancer and possibly attenuates patients' anxiety.
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The increased use of mammograms has led to the frequent
detection of breast lesions, which in turn require further
evaluation [1,2]. The most common mammographic
abnormalities found on screening examinations are
microcalcifications [3,4]. Radiographic mammary micro-
calcifications occur in 30–50% of breast cancer cases and
constitute one of the most important diagnostic markers
in both benign and malignant lesions of the breast [3,4].
When suspicious microcalcifications appear on a mam-
mogram, a needle localization core biopsy is recom-
mended, so that breast tissue can be removed and
examined under a microscope by a pathologist. Although
microcalcifications are the commonest radiological fea-
ture of ductal carcinoma in situ (DCIS), about 90% of
women with abnormal microcalcifications do not have
breast cancer; this highlights the importance of a safe and
efficient evaluation [5,6].
According to the Breast Imaging Reporting and Data Sys-
tem (BI-RADS) of the American College of Radiology, a
biopsy is suggested for lesions classified as category 4 (sus-
picious), and category 5 (highly suggestive of malignancy)
[7-9]. Additionally, a biopsy can be performed in category
3 lesions if the patient or the referring physician insists
[9,10]. Owing to the broad spectrum of the BI-RADS 4 cat-
egory and the corresponding wide range of malignancy
incidence within it, this category is subdivided into group
4A, 4B and 4C [9-11].
To establish a preoperative diagnosis, excisional biopsies,
core needle biopsies [12-14] and vacuum-assisted breast
biopsies (VABB) have been used [15,16]. VABB on the
Fischer's table has become an integral part of the work-up
of patients with suspicious breast lesions, as it is estab-
lished as a safe and effective technique providing a mini-
mally invasive, faster, and less painful method for
sampling microcalcifications seen on mammograms [17-
23].
Recently, core imprint cytology has been shown to have a
high sensitivity in diagnosing malignancy. Imprint cytol-
ogy is a technique that is used in our centre for breast spec-
imens obtained after the performance of VABB. As far as
breast cancer is concerned, imprint cytology has been
extensively discussed at the intraoperative level, for the
assessment of sentinel lymph nodes [24-27], and second-
arily at the preoperative level, i.e. diagnosis of breast car-
cinoma. The significance, rapidity and reliability of the
method have been documented in the context of needle
core biopsy [28-30]. However, to our knowledge, no stud-
ies have focused on imprint cytology specimens derived
from VABB. The purpose of this study is to evaluate the
application on imprint cytology on cores with microcalci-
fications derived from VABB.
Patients and methods
We describe our experience based on 93 procedures per-
formed for microcalcifications from January 2005 to Sep-
tember 2006, in our Breast Unit on women aged 35–75
years (50.66 ± 9.10, mean ± SD).
Before the VABB, all patients were evaluated by one of the
two radiologists assigned to the Breast Imaging Section.
For lesions categorized as BI-RADS 3, follow-up was gen-
erally recommended. However, VABB was performed in
cases where family history was strongly positive or when
the patient and referring physician expressed particular
concern. In our unit, BI-RADS category 5 cases were
directly submitted to open surgical biopsy (operation) in
view of the great likelihood of cancer. VABB was per-
formed on digital prone table (Mammotest, Fischer Imag-
ing, Denver, CO, USA) using 11-gauge Mammotome
vacuum probes, under local anesthesia. The examination
proceeded according to a standard protocol to assure
quality control. The surgeon attempted to procure 24 or
more cores in each instance. A mammogram of the cores
after the procedure confirmed the excision of microcalci-
fications.
For the application of imprint cytology only the cores with
microcalcifications confirmed by mammogram after the
procedure were used. On the other hand, for the establish-
ment of the final pathological diagnosis, all the cores
obtained by VABB were examined.
The cores were gently rolled against glass microscope
slides and thus imprint smears were made. For rapid pre-
liminary diagnosis: i) air dried smears were stained with a
Diff-Quick stain, ii) smears were fixed in 95% ethyl alco-
hol for 20 min and stained with a modified Papanicolaou
stain and iii) air dried smears were stained by May Grun-
wald Giemsa. Afterwards, the cores were dipped into a
CytoRich Red Collection fluid for a few seconds in order
to obtain samples with the use of the specimen wash.
After the completion of cytological procedures, the cores
were plunged into formalin and were prepared for routine
pathological study. The pathologist was blind to the pre-
liminary cytological results.
Permission has been obtained from the local institutional
review board for publication of the findings summarized
in this study.
Results
The sample comprised 93 specimens. Among them,
31.2% (29 out of 93) came from BI-RADS 3 lesions,
45.2% (42 out of 93) from BI-RADS 4A lesions, 22.5%
(21 out of 93) from BI-RADS 4B lesions and 1.1% from
BI-RADS 4C lesions (1 case). According to the pathologi-
cal examination, 73 lesions were benign (Table 1) and 15Page 2 of 6
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cases and 3 IDC cases. Five lesions were precursor (3 cases
of ADH and 2 cases of LN).
The results of imprint cytology vs. the pathological results
are shown in Table 2. Representative cases are shown in
Figures 1, 2, 3. The observed sensitivity of the cytological
imprints for cancer was 100% (15 true positive/15 malig-
nant cases), since no false negative results appeared. Sim-
ilarly, the specificity of the method for cancer was 100%,
given that there were no false positive cytological diag-
noses. Due to the fact that there was total identity of
results between the two methods, only the one-sided,
97.5% confidence interval could be calculated for both
proportions (sensitivity and specificity), and it was
78.2%–100%.
As far as precursor lesions are concerned, only one case of
ADH could be detected by imprint cytology, i.e. 33.3% of
ADH cases [95%CI: 0.8%–90.6%]; the other two cases
yielded false-negative imprints (i.e. having a benign
appearance). Neither of the 2 LN cases was detected by the
Table 2: MicrocalcificationCytological and pathological results along with BI-RADS classification
Cytological results
(with negative pathological results)
Cytological results










Benign 24 0 4 - - - 28
Cancer - - - 0 1 0 1
BI-RADS 4A
Benign 27 0 2 - - - 29
Precursor - - - 3 1a 1 b 5
Cancer - - - 0 8 0 8
BI-RADS 4B
Benign 11 0 5 - - - 16
Cancer - - - 0 5 0 5
BI-RADS 4C
Cancer - - - 0 1 0 1
Total 62 0 11 3 16 1 93
a this case is an ADH lesion
b this case is a LN lesion
Table 1: Spectrum of benign lesions in the sample
BIRADS classification
Histopathological diagnosis BI-RADS 3 BI-RADS 4A BI-RADS 4B Total
Fibrocystic change1 10 8 6 24
Fibroadenoma 2 3 1 6
Sclerosing adenosis 8 7 0 15
Adenosis 4 3 4 11
Papilloma 0 3 2 5
Ductal ectasia 2 3 2 7
Epitheliosis with atypia 1 1 0 2
Monckeberg calcific sclerosis 0 0 1 1
Periductal mastitis 1 1 0 2
Total 28 29 16 73
1As the sole finding; when fibrocystic changes coexisted with other, more important disorders, the case was attributed to the latter.Page 3 of 6
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other one a false negative (having a benign appearance)
cytological diagnosis.
Finally, the cytological imprints were uninformative in 11
out of 93 cases (11.8%), irrespectively of BI-RADS classi-
fication or histopathological diagnosis. 13.8% (4 out of
29) of BI-RADS 3 cases yielded uninformative specimens,
4.8% (2 out of 42) of BI-RADS 4A cases were uninforma-
tive, and the respective percentage was 23.8% (5 out of
21) for BI-RADS 4B lesions. It should be stressed that no
uninformative cases existed within the malignant sub-
group.
Discussion
The importance of anxiety in the management of breast
patients has been well demonstrated in the literature, even
during mild medical procedures [32,33]. It has been
reported that patients experience clinically marked levels
of anxiety while they undergo breast biopsy, irrespectively
of whether it is an open biopsy or core needle biopsy [34-
36]. Interestingly, the use of oral anxiolytic medication
has been proposed, in order to reduce anxiety women
experience [37].
An effective means of reducing anxiety could be a reliable
immediate diagnosis after VABB. A rapid answer could
represent a valuable relief for women, given that a patho-
logical diagnosis might take four to seven days to be
made. Imprint cytology is the technique that could give a
preliminary diagnosis within a few minutes.
The sensitivity and the specificity of the method regarding
malignancies seem to be absolutely satisfactory, since
both were 100% in the sample. The lack of false positive
diagnoses (specificity 100%) implicates that imprint use
is not capable of imposing unjustified additional anxiety
upon the patients. Additionally, the lack of false negative
results indicates that no tumors escape the method. It is
worth mentioning that uninformative samples were not
present among malignant cases and thus did not interfere
with cancer detection. Thus, a malignant diagnosis by
imprint cytology could be considered almost definitive
and the patients should be psychologically prepared for
the subsequent operation.
According to our sample, the main drawback of the
method pertains to the detection of precursor breast
lesions (ADH, LN). Due to the small number of ADH
Cytology imprint derived from a benign lesionFigure 3
Cytology imprint derived from a benign lesion.
Cytology imprint derived from a malignant lesionFigure 1
Cytology imprint derived from a malignant lesion.
Cytology imprint derived from another malignant lesionFigure 2
Cytology imprint derived from another malignant lesion.Page 4 of 6
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imprint cytology (33.3%) should be interpreted with cau-
tion. This is reflected upon the extremely large confidence
interval, which leaves open all possibilities for the future
development of the method. The clinicians should bear in
mind the problems of the method with respect to precur-
sor lesions, and should thus not over-reassure the patient,
unless the final pathologic diagnosis is established. Fur-
ther studies encompassing larger samples and focusing on
precursor lesions are needed.
Conclusion
This study is the first one to describe the application of
imprint cytology in the context of microcalcifications
excised by VABB. It demonstrates the very satisfactory sen-
sitivity and specificity of the method. Its capability to pro-
vide a rapid preliminary diagnosis in a few seconds and a
final cytological diagnosis the day after renders it particu-
larly attractive. Further studies, on larger samples are
needed to establish the method in the common clinical
practice.
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